Form 8-K - Current report:
SEC Accession No. 0001493152-23-009816
Filing Date
2023-03-30
Accepted
2023-03-30 17:04:15
Documents
15
Period of Report
2023-03-30
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 41982
2 ex99-1.htm EX-99.1 27086
3 ex99-1_001.jpg GRAPHIC 11458
  Complete submission text file 0001493152-23-009816.txt   309514

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE bct-20230330.xsd EX-101.SCH 3949
5 XBRL DEFINITION FILE bct-20230330_def.xml EX-101.DEF 26582
6 XBRL LABEL FILE bct-20230330_lab.xml EX-101.LAB 36619
7 XBRL PRESENTATION FILE bct-20230330_pre.xml EX-101.PRE 25206
9 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5448
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 8-K | Act: 34 | File No.: 001-40101 | Film No.: 23781588
SIC: 2834 Pharmaceutical Preparations